Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Trimmed by Geode Capital Management LLC

Geode Capital Management LLC reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.0% during the third quarter, Holdings Channel.com reports. The fund owned 1,114,778 shares of the specialty pharmaceutical company’s stock after selling 83 shares during the quarter. Geode Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $124,227,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Itau Unibanco Holding S.A. acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC grew its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 704 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Jazz Pharmaceuticals by 24.5% during the 2nd quarter. Blue Trust Inc. now owns 1,307 shares of the specialty pharmaceutical company’s stock valued at $139,000 after acquiring an additional 257 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Down 2.2 %

Jazz Pharmaceuticals stock opened at $122.49 on Wednesday. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $7.41 billion, a P/E ratio of 17.25, a P/E/G ratio of 1.02 and a beta of 0.57. The company’s fifty day simple moving average is $117.72 and its 200-day simple moving average is $112.36.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JAZZ. Needham & Company LLC restated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $177.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock worth $816,289 over the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.